Clinical trials: Allogeneic Disease
Myelodysplastic Syndromes, Acute Myelogenous Leukemia
Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
The hypothesis of this study is that lenalidomide can be an effective drug in preventing relapse of MDS and AML patients with chromosomal abnormalities involving monosomy 5 or del5q after allogeneic HSCT.
- Trial name
- LENAMAINT (NCT00720850)
- Testing
- lenalidomide
- Where
- 7 sites in Germany
- Volunteers
- 10 people
- Sponsor
- Technische Universität Dresden
Condition After Allogenic Peripheral Stem Cell Transplantation (SCT)
PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood
In this prospective study is to examine whether the use of everolimus in patients after allogeneic SCT as part of GVHD prophylaxis for a further review in clinical studies is appropriate.
- Trial name
- NCT01509560
- Testing
- Everolimus
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma
A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer
Patients in the Phase 1b part of the study will be treated with ilixadencel at an increasing dose and frequency, in combination with standard doses and schedules of checkpoint inhibitor (CPI) pembrolizumab.
- Conditions
- Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Non-small Cell Lung Cancer
- Trial name
- ILIAD (NCT03735290)
- Testing
- ilixadencel, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Mendus
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
This phase Ib trial tests the safety, side effects, best dose and effectiveness of tagraxofusp in combination with azacitidine as maintenance therapy in treating patients with CD123 positive acute myeloid leukemia (AML) and…
- Trial name
- NCT06498973
- Testing
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- City of Hope Medical Center
Acute Lymphoblastic Leukemia, B-cell Lymphoma
Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies
This is an open label, single-arm, Phase I study to evaluate the efficacy and safety of allogenic CD19-CAR-NK cells in subjects with refractory or relapsed B-cell hematologic malignancies.
- Conditions
- Acute Lymphoblastic Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT05739227
- Testing
- allogenic CD19-CAR-NK cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Xuzhou Medical University
Measurable Residual Disease
MRD Monitoring by Digital Droplet PCR in the Early Period After Allo-HSCT to Predict Patients at High Risk of Relapse
A study on the Effectiveness of digital droplet PCR in monitoring measurable residual disease during the early period after allogeneic hematopoietic stem cell transplantation to predict patients at high risk of relapse
- Trial name
- NCT06000306
- Testing
- Digital Droplet PCR
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Zhejiang University
Covid19
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise
This is a Phase 2a randomized, placebo-controlled study designed to investigate the efficacy, safety and tolerability of COVI-MSC in treating post COVID-19 "long haul" pulmonary compromise.
- Trial name
- BR (NCT04992247)
- Testing
- COVI-MSC
- Sponsor
- Sorrento Therapeutics, Inc.
Hepatocellular Carcinoma
Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma
This is a multicenter, open-label, paired control study to evaluate the safety and clinical efficacy of allogeneic NK cells combined with targeted drug in the treatment for advanced HCC.
- Trial name
- NCT04162158
- Testing
- allogeneic NK cells therapy
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Beijing 302 Hospital
Poor Graft Function, Myelodysplastic Syndromes
Anakinra for Prevention of Poor Graft Function in MDS Allo-HSCT
Preclinical evidence indicates that IL-1 inflammatory signaling suppresses bone marrow mesenchymal stromal cells (MSCs) from secreting stem cell factor (SCF), leading to failure of their hematopoietic supportive capacity, and…
- Conditions
- Poor Graft Function, Myelodysplastic Syndromes, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT07888348
- Testing
- Anakinra
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Ruijin Hospital
Graft-Versus-Host Disease
Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)
To test a new agent, LBH589, in combination with glucocorticoids as initial therapy of acute graft versus host disease (GVHD).
- Trial name
- NCT01111526
- Testing
- Panobinostat (LBH589)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Leukemia, Lymphoma
Allogeneic Transplant in HIV Patients (BMT CTN 0903)
The rationale for this trial is to demonstrate the feasibility and safety of allogeneic HCT for patients with chemotherapy-sensitive hematological malignancies and coincident HIV-infection.
- Conditions
- Leukemia, Lymphoma, HIV
- Trial name
- NCT01410344
- Testing
- Fludarabine and Busulfan, Fludarabine and Melphalan, Busulfan and Fludarabine
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- Medical College of Wisconsin
Acute GVH Disease
MTX and Steroid as First-line Therapy for aGVHD
The aim of the study is to identify the efficacy and safety of methotrexate (MTX) combined corticosteroid as first-line therapy for acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation…
- Trial name
- NCT04960644
- Testing
- MTX, Corticosteroid
- Where
- China
- Volunteers
- 157 people
- Sponsor
- Peking University People's Hospital
COVID-19, Sars-CoV2
Safety and Feasibility of Allogenic MSC in the Treatment of COVID-19
Coronavirus Disease 2019 (COVID-19) is spreading worldwide and has become a public health emergency of major international concern. Currently, no specific drugs or vaccines are available.
- Trial name
- COVID19 (NCT04467047)
- Testing
- Mesenchymal Stromal Cells infusion
- Volunteers
- 10 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Acute Leukemia, Chronic Leukemia
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
This is a phase 1, interventional single arm, open label, treatment study designed to evaluate the safety combination programmed cell death protein 1 (PD-1) and interleukin 6 (IL-6) inhibition in participants with relapsed…
- Conditions
- Acute Leukemia, Chronic Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT03588936
- Testing
- Nivolumab (.25 mg/kg), Tocilizumab, Nivolumab (.5 mg/kg)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Medical College of Wisconsin
Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT
HSCT from an allogeneic donor is the standard therapy for high-risk hematopoietic malignancies and a wide range of severe non-malignant diseases of the blood and immune system.
- Conditions
- Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, in Relapse, High Risk Acute Lymphoblastic Leukemia
- Trial name
- NCT05066958
- Testing
- boost anti-viral immunity after T-cell depleted HSCT
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Lymphoma
Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma
This research study is assessing the feasibility of reduced intensity allogeneic hematopoietic stem cell transplantation (HSCT) as a possible treatment for relapsed / refractory non-Hodgkin lymphoma involving the central nervous…
- Trial name
- NCT02724904
- Testing
- Allogeneic stem cell transplantation, Fludarabine, Thiotepa
- Where
- 2 sites in United States
- Sponsor
- Massachusetts General Hospital
Autism
Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy for Autism
Allogeneic (not from the subject) human umbilical cord tissue-derived stem cells administered intravenously (IV) in a series of 4 infusions every 3 months over the course of one year is safe and will induce a therapeutic effect…
- Trial name
- NCT02192749
- Testing
- Umbilical cord mesenchymal stem cells
- Where
- Panama
- Volunteers
- 20 people
- Sponsor
- Translational Biosciences
Acute Myeloid Leukemia
Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients
This is a single-arm, Phase II study of crenolanib as maintenance in AML patients with FLT3 mutations who have achieved complete remission (CR) after allogeneic stem cell transplantation.
- Trial name
- NCT02400255
- Testing
- Crenolanib besylate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Breast Cancer
Allogenic Haematopoietic Cell Transplantation for Patients With Refractory "Triple Negative" Breast Cancer
The purpose of this study is to evaluate the engraftment, toxicity and anti-tumour activity of allogeneic peripheral blood progenitor cell (PBPC) transplantation using TLI/ATG conditioning regimen in patients with refractory…
- Trial name
- NCT01375023
- Testing
- Radiotherapy, Anti-Thymocyte Globulin
- Where
- Italy
- Volunteers
- 3 people
- Sponsor
- European Institute of Oncology
Cytomegalovirus Infections
Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection
To evaluate the safety and efficacy for treatment of persistent CMV infection in hematopoietic cell transplant (HCT) recipients.
- Trial name
- NCT02346617
- Testing
- IFN-γ positive selected T-cells
- Where
- South Korea
- Sponsor
- Yae-Jean Kim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.